ArticleInternational journal of cell biology2010
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
Article in International journal of cell biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
186 citing papers in PubMed, 4 syntheses or guidelines pooled it, 468 citations in OpenAlex.
- The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Current oncology (Toronto, Ont.) · 2022Pooled it
- Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.The Cochrane database of systematic reviews · 2014Pooled it
- Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects.Disease markers · 2014Pooled it
- Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.JAMA oncology · 2026Trial
- COX2Physiological reports · 2026Article
- Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer.Inorganic chemistry · 2026Article
- Cyclooxygenase-2 (COX-2) as a Potential Prognostic Marker in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Bioactive compounds in European ferns: inhibition of pro-inflammatory enzymes and cytotoxic effects on cancer cells.BMC complementary medicine and therapies · 2026Article
- Fruitful Interventions: A Narrative Review Addressing the Emerging Role of Antioxidant Fruits in Combating IBD-Driven Colorectal Cancer.Mini reviews in medicinal chemistry · 2026Review
- The consequences of the extremely low frequency electromagnetic field (ELF-EMF) exposure on physiological processes in the uterus: novel insights and implications.Frontiers in physiology · 2026Review
- Prediction of high-quality human oocytes and embryos through the analysis of gene expression in cumulus cells.Journal of ovarian research · 2025Review
- Predictive biomarkers in the gut microbiome and metabolome for severe acute radiation enteritis in cervical cancer radiotherapy.Discover oncology · 2025Article
- Costunolide inhibits the progression of TPA-induced cell transformation and DMBA/TPA-induced skin carcinogenesis by regulation of AKT-mediated signaling.Cancer cell international · 2025Article
- Spatiotemporal characterization of cyclooxygenase pathway enzymes during vertebrate embryonic development.Developmental biology · 2025Article
- Nrf2/cyclooxygenase 2 signaling in Cr(VI)-induced carcinogenesis.Ecotoxicology and environmental safety · 2025Article
- Two-Step Cell Death Induction by the New 2-Arachidonoyl Glycerol Analog and Its Modulation by Lysophosphatidylinositol in Human Breast Cancer Cells.International journal of molecular sciences · 2025Article
- Tumor-specific cytotoxicity of pyrazole-based chalcone derivatives in human oral squamous cell carcinoma cell lines.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Cyclooxygenase-2 Overexpression and its Association with Histopathological Features of Human Malignant Melanoma.Iranian journal of pathology · 2025Article
- Divergent gene expression ofFrontiers in oncology · 2025Article
126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well admitted that the link between chronic inflammation and cancer involves cytokines and mediators of inflammatory pathways, which act during the different steps of tumorigenesis. The cyclooxygenases (COXs) are a family of enzymes, which catalyze the rate-limiting step of prostaglandin biosynthesis. This family contains three members: ubiquitously expressed COX-1, which is involved in homeostasis; the inducible COX-2 isoform, which is upregulated during both inflammation and cancer; and COX-3, expressed in brain and spinal cord, whose functions remain to be elucidated. COX-2 was described to modulate cell proliferation and apoptosis mainly in solid tumors, that is, colorectal, breast, and prostate cancers, and, more recently, in hematological malignancies. These findings prompt us to analyze here the effects of a combination of COX-2 inhibitors together with different clinically used therapeutic strategies in order to further improve the efficiency of future anticancer treatments. COX-2 modulation is a promising field investigated by many research groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.